Effect of nasal triamcinolone acetonide on lower airway inflammatory markers in patients with allergic rhinitis - 29/08/11
Abstract |
Background: Allergic rhinitis (AR) and asthma are commonly associated, and similar underlying inflammatory processes link both diseases. AR, even in the absence of asthma, is asso-ciated with increased levels of exhaled nitric oxide (ENO) and hydrogen peroxide (H2O2) in exhaled breath condensate, 2 noninvasive markers of lower airway inflammation. Objective: We sought to evaluate the effect of treatment with the nasal steroid triamcinolone acetonide on ENO and exhaled H2O2 in subjects with AR. Methods: We allocated 23 subjects in a randomized, double-blind, parallel-controlled fashion to 4-week treatment with triamcinolone acetonide (220 μg/d) or matching placebo. Results: ENO levels were greater in the subgroup with concomitant asthma (16/23 subjects) and decreased significantly with triamcinolone acetonide treatment in this subgroup of patients in comparison with patients receiving placebo. Breath condensate levels of H2O2 were higher in patients with AR without asthma than in those with asthma but decreased significantly with triamcinolone acetonide treatment in both subgroups. No changes were observed in bronchial hyperresponsiveness, nasal and asthma symptoms, or peak expiratory flow with active treatment or placebo. Conclusion: We conclude that treatment of AR with triamcinolone acetonide results in decrease of 2 noninvasive markers of lower airway inflammation, ENO and H2O2, supporting that upper and lower airway inflammation should be seen as a continuum in subjects with AR with and without asthma. ENO might be a more specific marker of the lower airway inflammation present in asthma. (J Allergy Clin Immunol 2003;111:313-20.)
Le texte complet de cet article est disponible en PDF.Keywords : Breath tests, triamcinolone, airways, inflammation, asthma, rhinitis
Abbreviations : AR, BHR, ENO, NasNO, NO, NOS
Plan
![]() | Supported by grants from CAPES, Brazil (Dr Alessandra Sandrini) and the Respiratory Research Fund of the Asthma and Airway Centre. |
![]() ![]() | Reprint requests: Kenneth R. Chapman, MD, Asthma and Airway Centre of The University Health Network, Suite 4-011 ECW, 399 Bathurst St, Toronto, Ontario, M5T 2S8, Canada. |
Vol 111 - N° 2
P. 313-320 - février 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?